Beyond the Burden: Surgical Innovations That Lengthen Treatment Interval...

455 11th Avenue at 38th Street,New York NY 10001

15 July, 2022

Description

Activity ChairCarl D. Regillo, MD, FACS Director, Retina Service Wills Eye Hospital Professor of Ophthalmology Thomas Jefferson University Mid Atlantic Retina Philadelphia, PA FacultyMargaret A. Chang, MD, MS Senior Partner Retinal Consultants of Sacramento Sacramento, CA Veeral Sheth, MD, MBA, FASRS Director of Clinical Research University Retina and Macula Associates Clinical Assistant Professor University of Illinois at Chicago Chicago, IL OverviewReducing treatment burden in patients receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for the management of retinal vascular diseases is imperative to address suboptimal outcomes through loss of patient adherence due to frequent dosing schedules. Refinement of treatment protocols have aimed to address this unmet need, yet most patients still require frequent dosing to maintain initial visual acuity gains. To address treatment burden, novel delivery systems have been developed that reduce the need for frequent dosing but require unique surgical approaches at the initiation of their use to achieve optimal efficacy and safety outcomes. Gene therapy is currently being evaluated in ongoing clinical studies, while the FDA-approved Port Delivery System (PDS) with ranibizumab has demonstrated maintenance of visual acuity gains with extended treatment intervals out to 6 months. In this CME activity, experts in the field will evaluate the evidence pertaining to new surgical innovations that can enhance outcomes by reducing treatment burden in patients with retinal vascular diseases, as well as provide guidance for best practices that can reduce the potential for complications when utilizing the PDS with ranibizumab or subretinal gene therapy for the management of patients with neovascular age-related macular degeneration (nAMD). Agenda6:15 PM Registration and Dinner 6:45 PM Introduction and Pretest Carl D. Regillo, MD 6:50 PM Surgical Innovations That Extend Treatment Intervals in nAMD and DME Carl D. Regillo, MD 7:05 PM The PDS and RGX314: Assessing New Evidence Margaret A. Chang, MD, MS 7:20 PM Panel Discussion: Best Practices for Incorporating the PDS Into Practice Moderated by Veeral Sheth, MD, MBA 7:40 PM Case Presentation With Video: Use of the PDS With Ranibizumab Moderated by Margaret A. Chang, MD, MS 7:50 PM Surgical Innovation QBank Moderated by Carl D. Regillo, MD 8:00 PM Posttest and Question & Answer 8:15 PM Conclusion Learning ObjectivesUpon successful completion of this activity, participants should be better able to: Examine new surgical advances that can enhance outcomes in patients with retinal vascular diseases by reducing treatment burden. Assess new evidence and best practices regarding the use of novel surgical interventions for the management of retinal vascular diseases. Describe best practices that can reduce the potential for complications when using the PDS or subretinal gene therapy for nAMD. Target AudienceThe intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal vascular diseases. This continuing medical education activity is provided by Vindico Medical Education. This activity is supported by an educational grant from Genentech, a member of the Roche Group. This program is not affiliated with ASRS. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity. Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity. Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.